SITE ATTACHMENT INHIBITION: NEW GENERATION IMMUNIZATION
Joint Event on 2nd WORLD OBESITY CONGRESS & International Conference on DIABETES AND ENDOCRINOLOGY & 2nd WORLD VACCINES AND IMMUNOLOGY CONGRESS
October 15-16 , 2018 | Tokyo , Japan
Melbourne University, Australia
Posters & Accepted Abstracts : Biomed Res
New Generation Immunization Programs. The current author anticipates site attachment inhibition therapeutics to include: (A) drug (medication) based therapies in treatment of established infections; (B) new generation immunization methods (as preventative treatment) utilizing stem cell based treatment (including prenatal and earlier, spanning back to oogenesis and spermatogenesis) termed stc based immunization in previous publications. With regards to new generation immunization programs, schedules to be developed would likely benefit from taking into consideration of the following. 1. Common infections to include taking into account the epidemiological characteristics of the given population. Also, 2. Additional vaccination that may be required for children being born with conditions predisposing them to particular infective agents. Hypothetical Examples: Should persons with hereditary immune dysfunction disorders receive additional immunizations? Should persons with cystic fibrosis receive additional protection? • For instance: Haemophilus influenza; P. aeruginosa? • Further research directed toward additional immunization, given likely hospital attendance, against Clostridium difficile. Note: there is currently a trial for a vaccine that is not stc based immunization, against Clostridium difficile. Clover Trial: https://clinicaltrials.gov/ct2/show/ NCT03090191. Interestingly, an article by the current author with regards to Clostridium Difficile: Raymond S (2017) Site Attachment Inhibition: Case Analysis Res HIV AIDS J SF 1: 1. Other infective agents and considerations for inclusion on schedules is a topic for further discussion. The medical profession may need to head toward the future. It may be worth considering whether such procedures should become routine as with procedure including amniocentesis.
Simon Raymond is a Consultant specializing in Medical and Scientific Research and an Alumnus of Melbourne University (Rank of Number 1 in Australia and Number 33 in the World). The above stated Researcher has acted as a Reviewer for the respected Medical Journal of Australia, has received invitations internationally to review from prestigious medical journals including Journal of American Medical Association Network. He has received award in recognition of his research by Royal Australasian College of Surgeons (PSC, 2006) and invited to conferences internationally as an official Delegate and Researcher, including that in USA and China. He has worked as the Principle Researcher in the highest-powered form of medical trial—Randomized Controlled Trial (RCT). The above stated Researcher is also a Member of the Golden Key International Society for Honored and outstanding Academics and has been cited as a Notable Global Leader.